SHP 656

Drug Profile

SHP 656

Alternative Names: BAX 826; Bax-826; Polysialylated rFVIII; PSA-FVIII - Shire/Xenetic Biosciences; PSA-rFVIII; SHP-826

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxter International; Xenetic Biosciences
  • Developer Shire; Xenetic Biosciences
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haemophilia A

Most Recent Events

  • 18 Jul 2017 Discontinued - Phase-II for Haemophilia A in Spain, Russia, Poland, Netherlands, Italy, Hungary, Germany, Bulgaria and United Kingdom due to lack of efficacy (Parenteral)
  • 03 Apr 2017 Xenetic Biosciences plans a phase III trial for Haemophilia A
  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top